MHRA Updates Oct 2020
- 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity
- Flucytosine (Ancotil): new contraindication in patients with DPD deficiency
- Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
- Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects
- Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic
- Every report counts: report suspected adverse drug reactions and take part in MedSafetyWeek (2–8 November 2020)
You can sign up to receive alerts directly at: MHRA email alerts
Published 04/11/2020. Medicines Update blogs are correct at the time of publication.